Skyhawk Therapeutics IPO

Skyhawk Therapeutics was founded in 2016 by Bill Haney and Kathleen McCarthy. Maura McCarthy, vice president of corporate development told reporters in 2021 that the company was likely to go public in the next 12 to 18 months, and that a $130 million fundraising round would be the last private fundraise before the company went public. The company remains private as of June 2023.

Skyhawk is a biotechnology company using its SkySTAR RNA splicing platform to develop new, small molecule drugs. The company has raised more than $600 million in venture capital and partnership funding. Investors include Fidelity Management & Research Company, Alexandria Venture Investments, GreatPoint Ventures, ShangPharma Innovation, and Agent Capital. Additionally, as of June 2023, the company maintains strategic partnerships with Bristol Myers Squibb, Merck & Co., and Vertex Pharmaceuticals. Skyhawk did not disclose valuation figures following a $133 million funding round in 2021.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Skyhawk Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Skyhawk Therapeutics

Forge green plus iconForge green minus icon

What is Skyhawk Therapeutics's IPO price?

The IPO price for Skyhawk Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Skyhawk Therapeutics?

Skyhawk Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Skyhawk Therapeutics shares pre-IPO?

If you own Skyhawk Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Skyhawk Therapeutics a publicly traded company?

Skyhawk Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

When was Skyhawk Therapeutics founded?

Skyhawk Therapeutics was founded in 2015.

Who are Skyhawk Therapeutics's major investors?

Fidelity Management & Research
Emerson Collective
GreatPoint Ventures
Bramalea Partners
Agent Capital
DNS Capital
DFE Capital Management
Sanofi Ventures
ShangBay Capital
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.